Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria.[L11830] It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps in the biosynthesis of nucleic acids and proteins which are necessary for bacterial growth and division, and using them in conjunction helps to slow the development of bacterial resistance.[L11830] In this combination, sulfamethoxazole is useful for the treatment of a variety of bacterial infections, including those of the urinary, respiratory, and gastrointestinal tracts.
Sulfamethoxazole and Trimethoprim (Double Strength)
Apo-sulfatrim Oral Suspension
Teva-trimel
Nu-cotrimox-DS Tab 800/160mg
SULFAMETHOXAZOLE and TRIMETHOPRIM
Protrin Tab
Septra DS
Bactrim DS Roche Tab
Sulfamethoxazole and Trimethoprim Tablets
Bactrim Roche Tab
Trisulfa S Suspension
Sulfamethoxazole and Trimethoprim Double Strength
Sulfamethoxazole and Trimethoprim DS
Bactrim Roche Suspension Paediatric
Septra Injection
Bactrim
Protrin Df Tab
Sulfameth/Trimeth-DS
Sulfamethoxazole Tab 500mg
Sulfamethox-TMP DS
Sulfamethoxazole and Trimethoprim
Sulfamethoxazole and Trimethoprim for Injection, USP
Teva-trimel DS
Nu-cotrimox Sus 40/8mg/ml
Sulfatrim DS
Apo Sulfamethoxazole Tab 500mg
Riva-sep DS
Septra Grape
sulfamethoxazole-trimethoprim (SMZ)
Sulfatrim Pediatric
SulfatrimTM Pediatric Suspension
Indication
Sulfamethoxazole is indicated in combination with trimethoprim, in various formulations, for the following infections caused by bacteria with documented susceptibility: urinary tract infections, acute otitis media in pediatric patients (when clinically indicated), acute exacerbations of chronic bronchitis in adults, enteritis caused by susceptible _Shigella_, prophylaxis and treatment of _Pneumocystis jiroveci_ pneumonia, and travelers' diarrhea caused by enterotoxigenic _E. coli_.[L11830,L11863] In Canada, additional indications include the adjunctive treatment of cholera, treatment of bacillary dysentery, nocardiosis, and second-line treatment of brucellosis in combination with [gentamicin] or [rifampicin].[L11851]
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
